CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.
Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent research, a team led by Dr. Armin Rehm presents an improved immunotherapy that ...
Neoantigens are unique markers that distinguish only cancer cells. By adding B cell reactivity, cancer vaccines can move ...
Lymphatic malformations (LMs) are congenital vascular anomalies characterized by abnormal lymphatic development, leading to ...
In hepatitis B virus (HBV) infection, the capacity to mount a functional virus-specific T-cell response has long been considered the principal, if not the sole, immunological determinant of viral ...
H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune DiseaseInterim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with ...
During a live event, Matthew Lunning, DO, interpreted long-term outcomes of the ZUMA-7 and TRANSFORM trials.
Autolus will evaluate Cellares’ fully automated, high-throughput manufacturing platform in preparation for expansion into new indicationsSOUTH SAN FRANCISCO, Calif. and LONDON, Jan. 06, 2026 (GLOBE ...
Verywell Health on MSN
What Happens to Your Immune System When You Take Vitamin C
It's true that vitamin C can give your immune system a boost, but when it comes to treating or preventing colds, things get a ...
A personal reflection on the promise and limits of CAR T therapy—its breakthroughs, failures, scientific bottlenecks, and what must change to truly save more lives.
Certain antibodies employ unusual tactics to keep germs from attaching to cells in our bodies. Their defensive strategies ...
Abbvie Inc. signed a $1.1 billion New Year’s Eve deal with China’s Zelgen Biopharmaceuticals Co. Ltd., gaining ex-China ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback